---
schema_version: "secwatch.filing_event.v1"
accession: "0001730463-23-000125"
form_type: "8-K"
ticker: "AUTL"
cik: "0001730463"
company_name: "Autolus Therapeutics plc"
filed_at: "2023-12-22T23:59:59+00:00"
generated_at: "2026-06-07T08:06:48.286946+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Autolus appoints Elisabeth Leiderman to board; Kapil Dhingra resigns

## Summary
- Kapil Dhingra resigned from Board effective Dec 31, 2023; not due to any disagreement with company.
- Elisabeth Leiderman appointed as Class II director effective Dec 20, 2023; will serve on Audit Committee.
- Leiderman receives £52,500 annual retainer, £6,500 audit committee retainer, and option to purchase 80,000 ADSs at $5.50.
- Leiderman most recently CFO/CBO of Atsena Therapeutics; also serves on bluebird bio board.
- Press release also notes BLA submission for obe-cel in r/r adult B-ALL to FDA.

## SEC filing metadata
- accession: 0001730463-23-000125
- form_type: 8-K
- ticker: AUTL
- cik: 0001730463
- company_name: Autolus Therapeutics plc
- filed_at: 2023-12-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730463/000173046323000125/0001730463-23-000125-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730463/000173046323000125/autl-20231219.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001730463-23-000125
- JSON: https://secwatch.observer/filing/0001730463-23-000125.json
- Plain text: https://secwatch.observer/filing/0001730463-23-000125.txt

## Key facts
- Executive change
  Kapil Dhingra resigned as Director at Autolus Therapeutics plc.
  - Action: resigned
  - Role: Director
  source text: On December 19, 2023, Kapil Dhingra, M.D. notified Autolus Therapeutics plc (the “Company”) of his intent to resign from the Board of Directors (the “Board”) of the Company and its committees, effective December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1730463/000173046323000125/0001730463-23-000125-index.htm
- Executive change
  Elisabeth Leiderman was appointed as Director at Autolus Therapeutics plc.
  - Action: appointed
  - Role: Director
  source text: On December 22, 2023, the Company announced that the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Elisabeth (“Lis”) Leiderman, M.D. to serve as a Class II director of the Company, effective December 20, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1730463/000173046323000125/0001730463-23-000125-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.